Alzheimer’s Disease: Exploring the Landscape of Cognitive Decline

Cites (293)

Items 201–292 of 292

1. Neurology and Clinical Neuroscience
   2007 · Elsevier eBooks
2. Leveraging generative AI to prioritize drug repurposing candidates for Alzheimer's disease with real-world clinical validation
   Yan, Chao, Grabowska, Monika E., Dickson, Alyson L., Li, Bingshan, Wen, Zhexing, Roden, Dan M., Michael Stein, C., Embí, Peter J., Peterson, Josh F., Feng, QiPing et al. · 2024 · npj Digital Medicine
3. DNA methylation in Alzheimer’s disease: In brain and peripheral blood
   Xueli Wei, Le Zhang, Yi Zeng · 2020 · Mechanisms of Ageing and Development
4. Amyloid and Tau Positron Emission Tomography Imaging in Alzheimer’s Disease and Other Tauopathies
   Cinzia Maschio, Ruiqing Ni · 2022 · Frontiers in Aging Neuroscience
5. Diabetes-Related Neurological Implications and Pharmacogenomics
   Camilo Andres Rojas-Carranza, Rosa‐Helena Bustos, Carmen Juliana Pino Pinzón, Yeimy Viviana Ariza Márquez, Rosa Margarita Gomez-Bello, Marisa Cañadas‐Garre · 2018 · Current Pharmaceutical Design
6. Leukocyte telomere length in mild cognitive impairment and Alzheimer's disease patients
   Daniela Scarabino, Elisabetta Broggio, Giuseppe Gambina, Rosa Maria Corbo · 2017 · Experimental Gerontology
7. SOBA: Development and testing of a soluble oligomer binding assay for detection of amyloidogenic toxic oligomers
   Dylan W. Shea, Elizabeth A. Colasurdo, Alec S.T. Smith, Courtnie Jean Paschall, Suman Jayadev, Christopher Dirk Keene, Douglas R Galasko, Andrew Lin Ko, Ge Li, Elaine R. Peskind et al. · 2022 · Proceedings of the National Academy of Sciences
8. Fit‐for‐Purpose Biometric Monitoring Technologies: Leveraging the Laboratory Biomarker Experience
   Godfrey, Alan, Vandendriessche, Benjamin, Bakker, Jessie P., Fitzer‐Attas, Cheryl, Gujar, Ninad, Hobbs, Matthew, Liu, Qi, Northcott, Carrie A., Parks, Virginia, Wood, William A. et al. · 2021 · Clinical and Translational Science
9. Hyperphosphorylated tau aggregation and cytotoxicity modulators screen identified prescription drugs linked to Alzheimer's disease and cognitive functions
   Mengyu Liu, Thomas Steven Dexheimer, Dexin Sui, Stacy Hovde, Xiexiong Deng, Roland P.S. Kwok, Daniel A. Bochar, Min‐Hao Kuo · 2020 · Scientific Reports
10. Comparison of plasma and CSF biomarkers in predicting cognitive decline
    Andrew J. Aschenbrenner, Yan Li, Rachel L. Henson, Katherine Volluz, Jason J. Hassenstab, Philip B. Verghese, Tim West, Matthew R. Meyer, Kristopher M. Kirmess, Anne M. Fagan et al. · 2022 · Annals of Clinical and Translational Neurology
11. A clinical dose of angiotensin-converting enzyme (ACE) inhibitor and heterozygous ACE deletion exacerbate Alzheimer's disease pathology in mice
    Shuyu Liu, Fujiko Ando, Yu Fujita, Junjun Liu, Tomoji Maeda, Xuefeng Shen, Kota Kikuchi, Aoi Matsumoto, Mirai Yokomori, Chiaki Tanabe et al. · 2019 · Journal of Biological Chemistry
12. Understanding PDE4's function in Alzheimer's disease; a target for novel therapeutic approaches
    Amy J. Tibbo, Gonzalo S. Tejeda, George S. Baillie · 2019 · Biochemical Society Transactions
13. Drug repurposing for Alzheimer’s disease from 2012–2022—a 10-year literature review
    Grabowska, Monika E., Huang, Annabelle, Wen, Zhexing, Li, Bingshan, Wei, Wei-Qi · 2023 · Frontiers in Pharmacology
14. Reduction of the expression of the late-onset Alzheimer’s disease (AD) risk-factor BIN1 does not affect amyloid pathology in an AD mouse model
    Andrew, Robert J., De Rossi, Pierre, Nguyen, Phuong, Kowalski, Haley R., Recupero, Aleksandra J., Guerbette, Thomas, Krause, Sofia V., Rice, Richard C., Laury-Kleintop, Lisa, Wagner, Steven L. et al. · 2019 · Journal of Biological Chemistry
15. Drug repurposing for Alzheimer’s disease: in silico and in vitro investigation of FDA-approved drugs as acetylcholinesterase inhibitors
    Navneet Kumar, Anuj Gahlawat, Rajaram Naresh Kumar, Yash Pal Singh, Gyan Prakash Modi, Prabha Garg · 2020 · Journal of Biomolecular Structure and Dynamics
16. Age-Related Neurodegeneration Prevention Through mTOR Inhibition: Potential Mechanisms and Remaining Questions
    Jordan B. Jahrling, Rémi-Martin Laberge · 2015 · Current Topics in Medicinal Chemistry
17. Role of primary aging hallmarks in Alzheimer´s disease
    Jin Zhao, Jisen Huai · 2022 · Theranostics
18. Blood-Based Biomarkers of Neuroinflammation in Alzheimer’s Disease: A Central Role for Periphery?
    Federica Angiulli, Elisa Conti, C Zoia, Fulvio Da Re, Ildebrando Marco Appollonio, Carlo Ferrarese, Lucio Tremolizzo · 2021 · Diagnostics
19. Altered mechanisms of protein synthesis in frontal cortex in Alzheimer disease and a mouse model.
    Paula Garcia‐Esparcia, Georgios Sideris-Lampretsas, Karina Hernández‐Ortega, Oriol Grau‐Rivera, Theodoros Sklaviadis, Ellen Gelpí, Isidró Ferrer · 2017 · Europe PMC (PubMed Central)
20. Cryo-EM of Aβ fibrils from mouse models find tg-APPArcSwe fibrils resemble those found in patients with sporadic Alzheimer’s disease
    Mara Zielinski, Fernanda S. Peralta Reyes, Lothar Gremer, Sarah Schemmert, Benedikt Frieg, Luisa U. Schäfer, Antje Willuweit, Lili Donner, Margitta Elvers, Lars N. G. Nilsson et al. · 2023 · Nature Neuroscience
21. Genetic studies in Alzheimer's disease
    Ya‐Ping Tang, Elliot S. Gershon · 2003 · Dialogues in Clinical Neuroscience
22. Nutrients, neurogenesis and brain ageing: From disease mechanisms to therapeutic opportunities
    Marco Fidaleo, Virve Cavallucci, Giovambattista Pani · 2017 · Biochemical Pharmacology
23. The Neuroprotective Effects and Therapeutic Potential of the Chalcone Cardamonin for Alzheimer’s Disease
    Kimberly Barber, Patricia Mendonca, Karam F. A. Soliman · 2023 · Brain Sciences
24. Cryo-EM observation of the amyloid key structure of polymorphic TDP-43 amyloid fibrils
    Kartikay Sharma, Fabian Stockert, Jayakrishna Shenoy, Mélanie Berbon, Muhammed Bilal Abdul-Shukkoor, Birgit Habenstein, Antoine Loquet, Matthias Schmidt, Marcus Fändrich · 2024 · Nature Communications
25. Telomeres in neurological disorders
    Ayyappan Anitha, Ismail Thanseem, Mahesh Mundalil Vasu, Vijitha Viswambharan, Suresh A. Poovathinal · 2019 · Advances in clinical chemistry
26. Does Alzheimer's disease with mesial temporal lobe epilepsy represent a distinct disease subtype?
    Ifrah Zawar, Jaideep Kapur · 2023 · Alzheimer s & Dementia
27. The effect of selective serotonin reuptake inhibitors on cognitive function in patients with Alzheimer’s disease and vascular dementia: focusing on fluoxetine with long follow-up periods
    Xie, Yi, Liu, Pei-Pei, Lian, Ya-Jun, Liu, Hong-Bo, Kang, Jian-Sheng · 2019 · Signal Transduction and Targeted Therapy
28. Stress and Alzheimer’s disease: A senescence link?
    Carey E. Lyons, Alessandro Bartolomucci · 2020 · Neuroscience & Biobehavioral Reviews
29. Current Anti-Amyloid-β Therapy for Alzheimer’s Disease Treatment: From Clinical Research to Nanomedicine
    Zhao, Zixuan, Liu, Yun, Ruan, Shirong, Hu, Yixuan · 2023 · International Journal of Nanomedicine
30. Familial Alzheimer's disease sustained by presenilin 2 mutations: Systematic review of literature and genotype–phenotype correlation
    Canevelli, Marco, Piscopo, Paola, Talarico, Giuseppina, Vanacore, Nicola, Blasimme, Alessandro, Crestini, Alessio, Tosto, Giuseppe, Troili, Fernanda, Lenzi, Gian Luigi, Confaloni, Annamaria et al. · 2014 · Neuroscience & Biobehavioral Reviews
31. TDP-43 as a therapeutic target in neurodegenerative diseases: Focusing on motor neuron disease and frontotemporal dementia
    Afshin Babazadeh, Stephanie L. Rayner, Albert Lee, Roger S. Chung · 2023 · Ageing Research Reviews
32. Telomere length associations with cognition depend on Alzheimer's disease biomarkers
    Emily R. Mahoney, Logan C. Dumitrescu, Mabel Seto, Kelly Nicole Holohan Nudelman, Rachel F. Buckley, Katie A. Gifford, Andrew J. Saykin, Angela Lee Jefferson, Timothy J. Hohman, Alzheimer’s Disease Neuroimaging Initiative · 2019 · Alzheimer s & Dementia Translational Research & Clinical Interventions
33. Blood Leukocyte Counts in Alzheimer Disease
    Jiao Min Luo, Jesper Qvist Thomassen, Børge Grønne Nordestgaard, Anne Tybjærg‐Hansen, Ruth Frikke‐Schmidt · 2022 · JAMA Network Open
34. Antidepressants in Alzheimer’s Disease: A Focus on the Role of Mirtazapine
    Ana Salomé Correia, Nuno Vale · 2021 · Pharmaceuticals
35. Neuroinflammation in Ischemic Stroke: Inhibition of cAMP-Specific Phosphodiesterases (PDEs) to the Rescue
    Laura Ponsaerts, Lotte Alders, Melissa Schepers, Rúbia Maria Weffort de Oliveira, Jos Prickaerts, Tim Vanmierlo, Annelies Bronckaers · 2021 · Biomedicines
36. Divergent Metabolic Regulation of Autophagy and mTORC1—Early Events in Alzheimer’s Disease?
    Mai Ahmed Shafei, Matthew Harris, Myra E. Conway · 2017 · Frontiers in Aging Neuroscience
37. In pursuit of degenerative brain disease diagnosis: Dementia biomarkers detected by DNA aptamer-attached portable graphene biosensor
    Tyler Andrew Bodily, Anirudh Ramanathan, Shanhong Wei, Abhijith G. Karkisaval, Nemil N. Bhatt, Cynthia Jerez, Md. Anzarul Haque, Armando Ramil, Prachi Heda, Yi Wang et al. · 2023 · Proceedings of the National Academy of Sciences
38. Epigenetic basis of Alzheimer disease
    Ángeles C. Tecalco-Cruz, Josué O. Ramírez‐Jarquín, María Elizbeth Álvarez-Sánchez, Jesús Zepeda–Cervantes · 2020 · World Journal of Biological Chemistry
39. Genetic of Alzheimer's Disease: A Narrative Review Article.
    Mohammad Khanahmadi, Dariush D Farhud, Maryam Malmir · 2015 · Europe PMC (PubMed Central)
40. Computational Drug Repurposing for Alzheimer’s Disease Using Risk Genes From GWAS and Single-Cell RNA Sequencing Studies
    Yun Xu, Jiming Kong, Pingzhao Hu · 2021 · Frontiers in Pharmacology
41. Incident stroke in patients with Alzheimer’s disease: systematic review and meta-analysis
    João Pinho, Miguel Quintas-Neves, Imis Dogan, Kathrin Reetz, Arno Reich, Ana Sofia Costa · 2021 · Scientific Reports
42. Reprogramming: Emerging Strategies to Rejuvenate Aging Cells and Tissues
    Alle, Quentin, Le Borgne, Enora, Milhavet, Ollivier, Lemaitre, Jean-Marc · 2021 · International Journal of Molecular Sciences
43. Late-onset dementia: a mosaic of prototypical pathologies modifiable by diet and lifestyle
    Mark P. Mattson · 2015 · npj Aging and Mechanisms of Disease
44. Neural Stem Cells in the Treatment of Alzheimer’s Disease: Current Status, Challenges, and Future Prospects
    Xiaokun Chen, Shenzhong Jiang, Renzhi Wang, Xinjie Bao, Yongning Li · 2022 · Journal of Alzheimer s Disease
45. Evaluation of Plasma Biomarkers for A/T/N Classification of Alzheimer Disease Among Adults of Caribbean Hispanic Ethnicity
    Lawrence S. Honig, Min Suk Kang, Annie Lee, Dolly Reyes‐Dumeyer, Angel L. Piriz, Belisa Soriano, Yahaira Franco, Zoraida Dominguez Coronado, Patricia Recio, Diones Rivera Mejía et al. · 2023 · JAMA Network Open
46. Network-based stage-specific drug repurposing for Alzheimer’s disease
    Kyriaki Savva, Margarita Zachariou, Marilena M. Bourdakou, Nikolas Dietis, George M. Spyrou · 2022 · Computational and Structural Biotechnology Journal
47. A Proteotranscriptomic-Based Computational Drug-Repositioning Method for Alzheimer’s Disease
    Lee, Soo Youn, Song, Min-Young, Kim, Dain, Park, Chaewon, Park, Da Kyeong, Kim, Dong Geun, Yoo, Jong Shin, Kim, Young Hye · 2020 · Frontiers in Pharmacology
48. Cognitive behavioural treatment for mild Alzheimer’s patients and their caregivers (CBTAC): study protocol for a randomized controlled trial
    Simon Forstmeier, Andreas Maercker, Egemen Savaskan, Tanja Roth · 2015 · Trials
49. International Alzheimer's Disease Research Portfolio (IADRP) aims to capture global Alzheimer's disease research funding
    Charlene Liggins, Heather M. Snyder, Nina B. Silverberg, Suzana S. Petanceska, Lorenzo M. Refolo, Laurie M. Ryan, María C. Carrillo · 2014 · Alzheimer s & Dementia
50. A systematic review and meta-analysis of plasma amyloid 1-42 and tau as biomarkers for Alzheimer’s disease
    Keerthanaa Balasubramanian Shanthi, Sreeram Krishnan, P Rani · 2015 · SAGE Open Medicine
51. Exploring the Causal Pathway From Telomere Length to Alzheimer’s Disease: An Update Mendelian Randomization Study
    Kai Gao, Wei Chen, Jin Liang Zhu, Xin Wang, Guoqing Chen, Yangyang Luo, Dai Zhang, Weihua Yue, Hao Yu · 2019 · Frontiers in Psychiatry
52. Blood Biomarkers in Alzheimer’s Disease
    Pravat Kumar Mandal, Joseph C. Maroon, Arun Garg, Narendra Kumar Arora, Rishu Bansal, Aditi Kaushik, Avantika Samkaria, Gayathri Kumaran, Yashika Arora · 2023 · ACS Chemical Neuroscience
53. TDP-43: A new player on the AD field?
    Katherine L. Youmans, Benjamin L. Wolozin · 2012 · Experimental Neurology
54. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Positive Modulator of HGF/MET, Fosgonimeton, in Healthy Volunteers and Subjects with Alzheimer’s Disease: Randomized, Placebo-Controlled, Double-Blind, Phase I Clinical Trial
    Xue Hua, Kevin J. Church, William Walker, Philippe L’Hostis, Geoffrey Viardot, Philippe Danjou, Suzanne Hendrix, Hans J. Moebius · 2022 · Journal of Alzheimer s Disease
55. Angiotensin-Converting Enzyme as a Potential Target for Treatment of Alzheimer's Disease: Inhibition or Activation?
    Kun Zou, Makoto Michikawa · 2008 · Reviews in the Neurosciences
56. PET Imaging in Animal Models of Alzheimer’s Disease
    Baosheng Chen, Bernadette V. Marquez-Nostra, Erika Belitzky, Takuya Toyonaga, Jie Tong, Yiyun Henry Huang, Zhengxin Cai · 2022 · Frontiers in Neuroscience
57. Advances in Therapeutics to Alleviate Cognitive Decline and Neuropsychiatric Symptoms of Alzheimer’s Disease
    Jialin Li, Alireza Ebrahimi, Afia B. Ali · 2024 · International Journal of Molecular Sciences
58. Signalling Pathways Implicated in Alzheimer′s Disease Neurodegeneration in Individuals with and without Down Syndrome
    Carmen Martínez‐Cué, Noemı́ Rueda · 2020 · International Journal of Molecular Sciences
59. Hematologic Risk Factors of Vascular Disease and Their Relation to Dementia
    Michelle M. Mielke, Peter P. Zandi · 2006 · Dementia and Geriatric Cognitive Disorders
60. Challenges in Designing Therapeutic Agents for Treating Alzheimer’s Disease-from Serendipity to Rationality
    Umer Rashid, Farzana Latif Ansari · 2014 · Elsevier eBooks
61. The first report of Alzheimer's disease
    Emmanuel Drouin, Guillaume Drouin · 2017 · The Lancet Neurology
62. Antidepressant Drugs: Mechanisms of Action and Side Effects
    Jane Pei‐Chen Chang, Arianna Zamparelli, Maria Antonietta Nettis, Carmine Maria Pariante · 2021 · Elsevier eBooks
63. Trait anxiety, a personality risk factor associated with Alzheimer’s Disease
    Song Li, Che Wang, Wei Wang, Jun Tan · 2020 · Progress in Neuro-Psychopharmacology and Biological Psychiatry
64. Vascular Dysfunction in Alzheimer’s Disease: Alterations in the Plasma Contact and Fibrinolytic Systems
    Ana Badimon, Daniel Torrente, Erin H. Norris · 2023 · International Journal of Molecular Sciences
65. BACE1 role in Alzheimer's disease and other dementias: from the theory to the practice
    Carlo Cervellati, Giuseppe Valacchi, Giovanni Zuliani · 2021 · Neural Regeneration Research
66. Alzheimer Disease
    Alena V. Savonenko, Tatiana Melnikova, Tong Li, Donald L. Price, Philip C. Wong · 2014 · Elsevier eBooks
67. Pharmacotherapy of Alzheimer’s Disease: Current State and Future Perspectives
    Jan Korábečný, Filip Zemek, Ondřej Soukup, Katarína Špilovská, Kamil Musílek, Daniel Jun, Eugenie Nepovimová, Kamil Kuča · 2014 · Elsevier eBooks
68. Recent High-Resolution Structures of Amyloids Involved in Neurodegenerative Diseases
    Rodrigo Díaz‐Espinoza · 2021 · Frontiers in Aging Neuroscience
69. Cognitive behavioral therapy (CBT) for preventing Alzheimer’s disease
    Larry D. Reid, Faith E. Avens, Alicia A. Walf · 2017 · Behavioural Brain Research
70. Addressing depression in older adults with Alzheimer’s through cognitive behavioral therapy: systematic review and meta-analysis
    Ana María González-Martín, Agustín Aibar‐Almazán, Yulieth Rivas-Campo, Noelia Rodríguez Sobrino, Yolanda Castellote‐Caballero · 2023 · Frontiers in Aging Neuroscience
71. Repurposing Licensed Drugs for Use Against Alzheimer’s Disease
    Leslie C. Norins · 2021 · Journal of Alzheimer s Disease
72. Early Detection of Alzheimer’s Disease-Related Pathology Using a Multi-Disease Diagnostic Platform Employing Autoantibodies as Blood-Based Biomarkers
    Cassandra A. DeMarshall, Jeffrey Viviano, Sheina Emrani, Umashanger Thayasivam, George A. Godsey, Abhirup Sarkar, Benjamin A. Belinka, David J. Libon, Robert G. Nagele, on behalf of the Parkinson’s Study Group and the Alzheimer’s Disease Neuroimaging Initiative · 2023 · Journal of Alzheimer s Disease
73. The Potential of a Stratified Approach to Drug Repurposing in Alzheimer’s Disease
    Chloe Anderson, Magda Bucholc, Paula L. McClean, Shudong Zhang · 2023 · Biomolecules
74. Modulation of Alzheimer’s Disease Aβ40 Fibril Polymorphism by the Small Heat Shock Protein αB-Crystallin
    Natalia P. Rodina, Simon Hornung, Riddhiman Sarkar, Saba Suladze, Carsten Peters, Philipp W. N. Schmid, Zheng Niu, Martin Haslbeck, Johannes Büchner, Aphrodite Kapurniotu et al. · 2024 · Journal of the American Chemical Society
75. E2814: an anti‐tau therapy engages its CNS target and affects the downstream tangle‐specific biomarker MTBR‐tau243 in Dominantly Inherited Alzheimer’s Disease
    Jin Zhou, Sumit Rawal, Takuya Yagi, Kristin R. Wildsmith, Eri Takahashi, Kanta Horie, Nicolas R. Barthélemy, Jagadeesh Aluri, Bojan B. Lalovic, Peter Boyd et al. · 2023 · Alzheimer s & Dementia
76. Monoclonal antibodies for treating early Alzheimer disease—a commentary on recent ‘positive’ trials
    Ian A Scott · 2024 · Age and Ageing
77. Neurofibrillary Tangles
    Heiko Braak, Kelly Del Tredici · 2010 · Elsevier eBooks
78. Mental activity may help prevent dementia
    Scott Gottlieb · 2003 · BMJ
79. Mapping the Spatial Distribution of Fibrillar Polymorphs in Human Brain Tissue
    Abdullah Al Bashit, Prakash Nepal, Theresa R. Connors, Derek H. Oakley, Bradley T. Hyman, Lin Yang, Lee Makowski · 2022 · Frontiers in Neuroscience
80. A model of lipid dysregulation and altered nutrient status in Alzheimer's disease
    Keith Fluegge · 2019 · Alzheimer s & Dementia Translational Research & Clinical Interventions
81. Drug repurposing strategy for treating Alzheimer’s disease
    Anik Kumar Kumar Das, Divya Sharma, Lalit Kumar Sharma · 2021 · Alzheimer s & Dementia
82. Immunostimulators and Immunomodulators in Cancer Treatment
    Brianna Oliver, Erica Jackson, Hatem H. Soliman · 2015 · Elsevier eBooks
83. Dementia
    Paul Johns · 2014 · Elsevier eBooks
84. Association of plant-rich dietary patterns of mediterranean and MIND with risk of alzheimer disease
    Sorayya Kheirouri, Fatemeh Valiei, Aliakbar Taheraghdam · 2024 · Human Nutrition & Metabolism
85. Alzheimer's Disease
    Emilija Veljkovic, Wenhao Xia, Blaine Wesley Phillips, Ee Tsin Wong, Jenny Ho, Alberto Oviedo, Julia Hoeng, Manuel C. Peitsch · 2018 · Elsevier eBooks
86. Premature Aging
    George M. Martin · 2007 · Elsevier eBooks
87. Medication Development for Amphetamine Dependence
    Keith G. Heinzerling · 2013 · Elsevier eBooks
88. Alzheimer's Disease
    Michael J. Murray, Catherine Friederich Murray · 2007 · Elsevier eBooks
89. Angiotensin Converting Enzyme (ACE) expression in microglia reduces amyloid β deposition and neurodegeneration by increasing SYK signaling and endolysosomal trafficking
    Andrew R. Gomez, Hyae Ran Byun, Shaogen Wu, AKM Ghulam Muhammad, Jasmine Ikbariyeh, Jaelin Chen, Alek Muro, Lin Li, Kenneth E. Bernstein, Richard I. Ainsworth et al. · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
90. Key psychosocial interventions for Alzheimer's disease: an update.
    Edmund G. Howe · 2008 · Europe PMC (PubMed Central)
91. Alzheimer's disease
    Andrew E. Budson, Paul R. Solomon · 2011 · Elsevier eBooks
92. Alzheimer's Disease
    Rachelle Smith Doody · 2006 · Elsevier eBooks